Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial

Affiliations

¹ Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
² bluebird bio, Cambridge, Massachusetts, USA.
³ Division of Hematology, Oncology & Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
⁴ Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
⁵ Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
⁶ Division of Hematology/Oncology, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
⁷ Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
⁸ Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
⁹ Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
¹⁰ University of California San Francisco, Benioff Children's Hospital Oakland, Oakland, California, USA.

Free article

Clinical Trial

John F Tisdale et al. Am J Hematol. 2020 Sep.

Free article

. 2020 Sep;95(9):E239-E242.

doi: 10.1002/ajh.25867. Epub 2020 Jun 3.

¹ Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
² bluebird bio, Cambridge, Massachusetts, USA.
³ Division of Hematology, Oncology & Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
⁴ Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
⁵ Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
⁶ Division of Hematology/Oncology, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
⁷ Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
⁸ Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
⁹ Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
¹⁰ University of California San Francisco, Benioff Children's Hospital Oakland, Oakland, California, USA.

No abstract available

References

1. Lagresle-Peyrou C, Lefrere F, Magrin E, et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica. 2018;103(5):778-786.
1. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11(4):464-471.
1. Esrick EB, Manis JP, Daley H, et al. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Adv. 2018;2(19):2505-2512.
1. Boulad F, Shore T, van Besien K, et al. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018;103(5):770-777.
1. Uchida N, Leonard A, Stroncek D, et al. Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica. 2020:236182. https://doi.org/10.3324/haematol.2019.236182. (Epub ahead of print).